Oncolytics Biotech® Announces Clinical Supply Agreement to Evaluate Pelareorep in Combination with LOQTORZI® (toripalimab-tpzi) in Squamous Cell Anal Carcinoma
Globe Newswire•11/11/2026•16:05 ET
0
Key Highlights
- ➤Oncolytics and Coherus entered a clinical supply agreement for pelareorep-LOQTORZI combination study
- ➤Study expected to begin Q1 2027 in second-line squamous cell anal carcinoma
- ➤Study will enroll patients progressing after chemotherapy and checkpoint inhibition
- ➤No approved second-line therapy currently exists for this indication
- ➤Results could support broader evaluation across HPV-associated cancers
Expert Statements
Jared Kelly, Chief Executive Officer of Oncolytics Biotech
“This agreement supports a focused clinical evaluation of pelareorep with a marketed PD-1 inhibitor in a difficult-to-treat patient population.”
Jared Kelly, Chief Executive Officer of Oncolytics Biotech
“The planned study is designed to build upon the previous efficacy signals pelareorep has shown in second-line or later SCAC patients while getting data in a patient population that has progressed on the new first-line standard of care.”
Jared Kelly, Chief Executive Officer of Oncolytics Biotech
“If the results are supportive, we believe SCAC could provide an important first step toward evaluating this combination more broadly across HPV-associated cancers.”
Pelareorep and toripalimab combine potentially complementary mechanisms designed to enhance antitumor immune responses and help overcome tumor immune resistance
Study may represent a first step toward evaluating the combination more broadly across HPV-associated cancers
Get started
Create a free account to read the full story.